Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Oct:99:108027.
doi: 10.1016/j.intimp.2021.108027. Epub 2021 Jul 31.

Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials

Ching-Yi Chen  1 , Wang-Chun Chen  2 , Chi-Kuei Hsu  3 , Chien-Ming Chao  4 , Chih-Cheng Lai  5
Affiliations
Meta-Analysis

Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials

Ching-Yi Chen et al. Int Immunopharmacol. 2021 Oct.

Abstract

Objectives: This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to investigate the clinical efficacy and safety of Janus kinase (JAK) inhibitors for COVID-19 patients.

Methods: PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched from inception to July 12, 2021. RCTs comparing the clinical efficacy and safety of JAK inhibitors with a placebo or standard care in treating COVID-19 patients were included. The primary outcome was all-cause mortality rate at day 28.

Results: Three RCTs were included in this meta-analysis. The all-cause mortality rate at day 28 was lower among the patients receiving JAK inhibitors than among the controls (4.1% [28/647] versus 7.0% [48/684], OR, 0.57; 95% CI, 0.36-0.92, I2 = 0). The clinical recovery rate was higher among the patients receiving JAK inhibitors than among the controls (85.1% (579/680) versus 80.0% [547/684], OR, 1.45; 95% CI, 1.09-1.93, I2 = 0). Additionally, the use of JAK inhibitors was associated with a shorter time to recovery than among the controls (MD, -2.84; 95% CI, -5.56 to -0.12; I2 = 50%). The rate of invasive mechanical ventilation (MV) was lower in the patients who used JAK inhibitors than among the controls. Finally, no significant difference was observed between the patients who used JAK inhibitors and the controls in the risk of any adverse events (OR, 0.92; 95% CI, 0.64-1.34; I2 = 33%) and serious adverse events (OR, 0.80; 95% CI, 0.45-1.44; I2 = 46%).

Conclusions: JAK inhibitors can lead to a better clinical outcome of hospitalized COVID-19 patients, and they are a safe agent in the treatment of COVID-19.

Keywords: And tofacitinib; Baricitinib; COVID-19; Janus kinase inhibitor; Ruxolitinib.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Algorithm of study selection. CENTRAL, Cochrane Central Register of Controlled Trials.
Fig. 2
Fig. 2
Summary of risks of bias in each domain.
Fig. 3
Fig. 3
Forest plot of the comparison of all-cause mortality rate at day 28 between the patients who received JAK inhibitors and the control group.
Fig. 4
Fig. 4
Forest plot of the comparison of clinical recovery rate between the patients who received JAK inhibitors and the control group.
Fig. 5
Fig. 5
Forest plot of the comparison of the risk of mechanical ventilation use between the patients who received JAK inhibitors and the control group.
Fig. 6
Fig. 6
Forest plots of comparisons of the risk of adverse events (A) and serious adverse events (B) between the patients who received JAK inhibitors and the control group.
Fig. 6
Fig. 6
Forest plots of comparisons of the risk of adverse events (A) and serious adverse events (B) between the patients who received JAK inhibitors and the control group.
See this image and copyright information in PMC

References

    1. Lai C.C., Shih T.P., Ko W.C., Tang H.J., Hsueh P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int. J. Antimicrob. Agents. 2020;55 - PMC - PubMed
    1. WHO. https://covid19.who.int/?gclid=CjwKCAjwiLGGBhAqEiwAgq3q_qP6pRDB-zQNmYa-d... Accessed on June 18, 2021.
    1. Berlin D.A., Gulick R.M., Martinez F.J. Severe Covid-19. N Engl J Med. 2020;383:2451–2460. - PubMed
    1. Lai C.C., Liu Y.H., Wang C.Y., Wang Y.H., Hsueh S.C., Yen M.Y., et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J. Microbiol. Immunol. Infect. 2020;53:404–412. - PMC - PubMed
    1. Hurt A.C., Wheatley A.K. Neutralizing antibody therapeutics for COVID-19. Viruses. 2021;13 - PMC - PubMed